SRRA - SRRA STOCK NEWS

Sierra Oncology, Inc. (NASDAQ: SRRA) announced new retrospective analyses of momelotinib from the Phase 3 SIMPLIFY studies, to be presented at the 63rd American Society of Hematology Annual Meeting in Atlanta from December 11-14, 2021. The findings highlight that baseline serum ferritin levels can predict Week 24 Transfusion Independence Response in myelofibrosis patients treated with momelotinib compared to ruxolitinib. Additionally, top-line data from the MOMENTUM clinical trial are expected by February 2022, with plans for a New Drug Application filing with the FDA in Q2 2022, pending positive results.

Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on targeted therapies for rare cancers, has granted stock options to three new employees as part of its 2018 Equity Inducement Plan. The options total 22,500 shares with an exercise price of $21.05 each, equivalent to the stock's closing price on the grant date. Vested shares will occur as 25% at the first anniversary and the remaining 75% in monthly installments over three years, contingent on continued employment.

Sierra Oncology (SRRA), a biopharmaceutical company focused on rare cancer therapies, has granted stock options to two new employees as part of its 2018 Equity Inducement Plan. The total options granted amount to 35,250 shares, with an exercise price of $22.43 for 27,000 options and $21.92 for 8,250 options, matching the closing stock prices at grant. The options will vest over time, promoting employee retention. This move aligns with Sierra's commitment to advance targeted therapies in oncology.

Sierra Oncology (NASDAQ: SRRA), a late-stage biopharmaceutical company, will participate in three investor conferences during September 2021. CEO Stephen Dilly will provide updates at the HC Wainwright 23rd Annual Global Investment Conference on September 13, Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on September 21, and engage in a fireside chat at the Cantor Virtual Global Healthcare Conference on September 28. All presentations will be webcasted and available on the company's website.

Sierra Oncology (SRRA), a late-stage biopharmaceutical company, has granted stock options to five new employees, totaling 40,700 shares. The options have an exercise price of $19.83 per share, matching the closing stock price on the grant date. The vesting schedule includes 25% after one year and the remainder in 36 monthly installments. This grant falls under the 2018 Equity Inducement Plan, aimed at attracting new talent to support its mission in developing targeted therapies for rare cancers.

Sierra Oncology (NASDAQ: SRRA) has updated its development timeline for momelotinib, expecting topline data from the Phase 3 MOMENTUM study by February 2022. Assuming positive results, a New Drug Application will be filed with the FDA in Q2 2022. The company also raised $34 million through its at-the-market offering, adding to $90.7 million in cash on hand. Sierra anticipates an additional $33.3 million from Series B warrants. CEO Stephen Dilly highlighted the company's strong position ahead of topline data release.

Sierra Oncology, Inc. (SRRA) announced its Q2 2021 financial results, reporting a GAAP net loss of $20.6 million, up from $16.5 million in Q2 2020. R&D expenses rose to $14.1 million due to increased clinical trial costs for momelotinib. The company completed enrollment for the MOMENTUM Phase 3 trial with 195 patients enrolled, exceeding the target of 180, and expects top-line data in Q1 2022. Sierra also in-licensed AZD5153 from AstraZeneca and plans further studies to explore combination therapies.

Sierra Oncology (NASDAQ: SRRA) has secured an exclusive global license from AstraZeneca for AZD5153, a selective BRD4 inhibitor. This acquisition aims to enhance treatment options for myelofibrosis, with a Phase 2 study planned using AZD5153 in combination with momelotinib. The upfront payment and milestones will support the trial, with Sierra leading all development activities. This strategic move reflects Sierra's commitment to expanding its pipeline of therapies for rare cancers, particularly targeting unmet needs in myelofibrosis treatment.

Sierra Oncology, Inc. (SRRA) has granted stock options to three new employees under its 2018 Equity Inducement Plan, as approved by the Compensation Committee. The total options granted amount to 23,250 shares, with an exercise price of $18.05 per share, equal to the closing price on the grant date. The options will vest 25% on the first anniversary of employment, followed by 75% in 36 equal monthly installments, contingent on the employees' continued employment. This initiative emphasizes Sierra's strategic approach to attract talent as it focuses on targeted cancer therapies.